Andy Plump (Jeff Rumans for Endpoints News @ JPM19)
February 6, 2020 07:59 AM ESTUpdated 09:21 AM
R&D
Cell/Gene Tx

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

Jason Mast

Editor

As far as bi­o­log­i­cal brand­ing goes, it’s hard to beat nat­ur­al killer cells.

These im­mune re­spon­ders earned their moniker in the ’70s for their ap­par­ent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times